Information from clinical and pharmacokinetic studies of angiotensin-converting enzyme inhibitors (ACEIs) has come from subjects who are mostly male and Caucasian, but the use of ACEIs extends to populations worldwide. Significant differences between Chinese in general and male Caucasians have been demonstrated in the pharmacokinetics/dynamics of other drug classes that could have implications for the use of ACEIs in the Chinese population. These include: significant Chinese/Caucasian genetic variation in the renin-angiotensin system based on an insertion/deletion (O/D) polymorphism of the ACE gene; the genetic determination of plasma ACE activity in the Chinese population; and genetic factors involving the disease substrate which may also influence the response to treatment. Oral and IV pharmacokinetic data from various studies of Chinese and Caucasian subjects are available for cilazapril, fosinopril, and perindopril, and pharmacodynamic data are available for eight different ACEIs. Based on these data, there are few differences among the pharmacokinetics of ACEIs between Chinese and Caucasians. Most
Introduction
Benefits from the use of angiotensin-converting enzyme inhibitors (ACEIs) have far exceeded the expectations of their early developers, and their numbers and indications have proliferated. The compounds differ in whether they: are or are not prodrugs; contain a sulfhydryl, carboxyl, or phosphinyl group as the zinc ligand with ACE; are metabolised by kidney (most of them), partially by liver or not at all; are excreted by kidney or, in one case, by kidney and liver; and are short-or long-act-ing. The vast majority of information from clinical studies of ACEIs has come from subjects who are male and Caucasian, but the use of ACEIs extends to populations worldwide. Only a modest number of studies have been carried out in the Chinese population, the world's largest single ethnic group, and significant differences between Chinese in general and male Caucasians have already been demonstrated in the pharmacokinetics/dynamics of other drug classes. 1 These differences could have implications for the use of ACEIs in the Chinese population where they are already involved in large trials along with nifedipine (Syst-China hypertension study in elderly Chinese 2 ) and in post-myocardial infarction (MI) patients using captopril (Chinese Cardiac Study (CCS-1) 3 .)
Genetic differences in the reninangiotensin system (RAS) and in RASrelated treatment
There is significant genetic variation in the RAS based on an insertion/deletion (I/D) polymorphism in intron 16 of the ACE gene. 4 This variation may affect circulating levels of ACE 5 as well as susceptibility to myocardial infarction, among other conditions. 6 In Caucasians, 44% of the variance in circulating ACE activity is accounted for by genetic polymorphism. 5 In a meta-analysis of studies composed mostly of Caucasians, the distribution of the I/D polymorphism was 22.7% II, 49% ID, and 28.3% DD, with the ACE levels of DDs about twice that of IIs 6 (for further review see Singer et al). 7 Plasma ACE activity is also genetically determined in the Chinese population, 8 but there is a much higher prevalence of the I allele (0.70 among Chinese 9 compared to 0.43 in a Caucasian population 5 ), and fewer have the D/D phenotype among Chinese than Caucasians. [9] [10] [11] [12] The association of I/D polymorphism with hypertension in Chinese appears weak 13 and perhaps confined to males over 40 years of age, 14 or absent. 8 There appears to be no association with coronary artery disease (CAD), myocardial infarction, and ischaemic cardiomyopathy, [9] [10] [11] [12] 15, 16 nor with insulin resistance 17 in Chinese. Unlike Caucasians, 18, 19 the T174M and M235T polymorphisms of the angiotensinogen (AGT) gene appear not to be associated with MI or CAD in Chinese. 20, 21 Finally, genetic polymorphisms may unexpectedly influence the action of a drug 22 and, independent of the ACE gene I/D polymorphism, a possible polymorphic response of ACE to the ACEI enalaprilat has been reported in Chinese subjects. 23 In addition to genetic factors influencing the RAS, genetic factors involving the disease substrate may also influence the response to treatment. For instance, data from MIDAS 24 and GLANT 25 (conducted in Europe and the US), suggest that short-acting dihydropyridines, while controlling blood pressure, do not reduce mortality and may increase cardiovascular events at higher doses. In contrast, data from a Chinese megatrial (STONE) 26 with dihydropyridines demonstrate effective blood pressure reduction and a reduction in mortality. Perhaps these differential effects are related to the low prevalence of coronary artery disease in Chinese compared to that in Europe and the US.
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Pharmacokinetics of ACEIs in Chinese and Caucasians
Oral pharmacokinetic data from various studies of Chinese and Caucasian subjects are available for cilazapril, 28 fosinopril, 29, 30 and perindopril 31 ( Table 1) . These data make possible comparisons of singledose pharmacokinetics between normal Chinese and Caucasian subjects for cilazapril, perindopril and fosinopril. For fosinopril there are additional singledose and steady-state comparisons of pharmacokinetics available among Chinese and Caucasian patients with congestive heart failure (CHF) as well as with CHF and renal insufficiency.
Cilazapril
Cilazapril is a carboxyl-containing ACEI designed for once-a-day administration and given as the prodrug which is converted to cilazaprilat, the active ACEI. It is excreted by the kidneys. 32 Cilazapril pharmacokinetics were studied in 12 healthy Chinese and 13 healthy Caucasians using single 2.5 mg oral doses. 28 Plasma concentrations were similar across time for both races ( Table 1 , rows 1 and 2 and Figure 1a ). The only difference between the groups was in plasma clearance which was significantly higher in Chinese even when adjusted for weight. No data were obtained to determine a doseresponse.
Fosinopril
Fosinopril is a phosphinic acid ACEI designed for once-a-day administration and given as the prodrug which is converted to fosinoprilat, the active ACEI. It has dual excretory pathways, renal and hepatic. 33 Fosinopril pharmacokinetics have been studied in 12 healthy Chinese and 10 healthy Caucasians using single 10.0 mg oral doses. 29, 34 Data were combined from two studies which used the same methods and analytic techniques (one in Chinese 29 and one in Caucasians 34 ). Plasma concentrations across time (Table 1 , rows 5 and 6 and Figure 1b) and renal clearance were similar in Chinese and Caucasians. Percent urinary excretion was identical. 29 Pharmacokinetics have also been obtained from 23 Chinese with heart failure (CHF) who received randomly allocated doses of 10, 20 or 40 mg/d oral fosinopril in three sequences of 10-14 days each. 30 Because of the protocol design no single-dose parameters could be obtained. At steady-state, following the 10 mg daily dose, pharmacokinetic values of AUC, C max , and T max were similar to values derived from 12 Caucasians with CHF and renal insufficiency who were studied separately 30 (Table 1 , rows 9 and 10). Higher doses were not studied in the Caucasian group. In order to assess the comparability of the steady-state data with single dose data, one can compare single-dose data from the same CHF/renal insufficiency Caucasians with singledose data from other Caucasian subjects with CHF 34 (Table 1 , rows 7 and 8) and with single-dose data in healthy Chinese 29 ( Table 1 , row 5). Taken together, no significant differences appear among any of these groups nor with the dose-independent parameters of T max (3.0 h) and elimination t . (11.3 h) in Caucasian CHF patients from another single-dose study. 35 In CHF, where either the hepatic or renal elimination pathways may be affected, higher drug doses could produce adverse effects in the absence of dose proportionality. However, at steady state, over the oral fosinopril doses of 10, 20 and 40 mg/d there was dose proportionality in the Chinese CHF patients as indicated by both AUC and C max (Table 2) .
Finally, in studies of fosinoprilat after i.v. administration in 12 healthy Chinese and nine healthy whites, there were statistically significantly lower values for renal clearance, non-renal clearance and total clearance in Chinese than white subjects. 36 () = ±s.e. for cilazaprilat and ±s.d. for fosinoprilat except for T max and C max /AUC for fosinoprilat. *P = Ͻ0.05 Chinese vs Caucasian. This difference was not significant when adjusted for weight. All other differences = NS. NA = not available; CHF = congestive heart failure; RI = renal insufficiency.
Perindopril
Perindopril is a carboxyl-containing ACEI designed for once-a-day administration and given as the prodrug which is converted to perindoprilat, the active ACEI. It is predominantly metabolically eliminated and excreted by the kidneys. 37 Perindopril pharmacokinetics were studied in 12 healthy Chinese and 10 healthy Caucasians using single 4.0 mg oral doses. 31 For perindopril, the rate of the absorption phase was significantly higher in Chinese, perhaps due to more rapid gastric emptying. Plasma concentrations remained slightly higher for Chinese, but this was, for the most part, accounted for by bodyweight adjustment (Table 1 , rows 3 and 4 and Figure  1c ). Percent urinary excretion was similar in Chinese and Caucasians. There were no other pharmacokinetic differences. No dose-response data were obtained. A small food effect, 38 which reduces the extent of ACE inhibition in Caucasian populations, was not evaluated in Chinese.
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Pharmacodynamic effects of ACEIs on the RAS in Chinese
Cilazapril At a 2.5 mg dose, ACE inhibition was similar in Chinese and Caucasians with almost 100% inhibition at 2 h, greater than 90% inhibition at 6 h, about 75% at 12 h, and about 50% at 24 h (Table 3) . Baseline plasma aldosterone concentrations tended to be higher in Chinese and the increase in plasma renin activity (PRA) in response to ACE-inhibition appeared to be greater. The authors speculated that this could reflect dietary differences or racial differences in the sensitivity of the RAS.
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Fosinopril
At a 10 mg dose, ACE inhibition of 100% was achieved at 1 h, maintained at 99% through 8 h, and 84% at 24 h in normals. 29 In heart failure patients, steady-state ACE inhibition was 82% at the 10 mg/d dose and Ͼ90% at higher doses 30 (Table 3) . Other indices of RAS activity have not been reported. These results were similar to those found for Caucasians, both normal 34 and with heart failure, and in single or steady-state dosing.
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Perindopril
Maximum ACE inhibition with the 4.0 mg dose studied was 88% at 5-6 h and appeared to fall below 80% after 8 h. 31 Aldosterone and PRA were reduced in both groups by 8 h but had returned to baseline by 48 h. The authors concluded that minor differences in pharmacokinetics between healthy Chinese and Caucasians have no significant effects on the pharmacodynamics of perindopril, although weight adjustment may be more commonly required in the lighter weight Chinese population.
Clinical pharmacodynamics of ACEIs in Chinese
Eleven studies 3, 28, 31, [40] [41] [42] [43] [44] [45] [46] [47] have reported clinical pharmacodynamic results of ACEIs in Chinese using eight different ACEIs ( Table 4 ). Eight of these 11 studies have been in hypertensives, 28 ,31,42-47 one in post-MI patients, 3 one in chronic renal failure patients, 40 and one has examined the occurrence of cough. 41 Among the eight hypertensive studies, three compared an ACEI with a calcium antagonist and found: enalapril less effective than nifedipine; 42 lisinopril equal to diltiazem; 43 and spirapril equal to isradipine 46 in antihypertensive effect. Benazepril and captopril were equal in a Chinese group. 45 In singledose studies comparing Chinese and Caucasian groups perindopril was equally effective, 31 but cilazapril appeared to have a lesser effect 28 in Chinese. In both the cilazapril and perindopril trials there was a significant and prolonged increase in heart rate in Chinese not found in the comparative Caucasian group. The authors speculated that this effect may have resulted in part from higher weight-related doses in Chinese, although the blood pressure effect was similar. In an 8-week trial in mild to moderate Chinese hypertensives, fosinopril lowered average blood pressure 23/15 mm Hg by cuff and 18/13 mm Hg by ambulatory blood pressure measurement. 47 Heart rate was unchanged from baseline. An early (4 week) report from the large Chinese Cardiac Study in post-MI patients showed a nonsignificant reduction in death with captopril. 3 A study comparing a Chinese herbal drug, Rheum E, with captopril for the prevention of renal failure found Rheum E superior to captopril, but the combination of the two drugs superior to either alone. 40 In a case-control study in the Chinese population the incidence of persistent cough in patients taking ACEIs (captopril and enalapril) was 44% (among 191 patients) compared to 11.1% (among 382 patients) in controls not taking ACEIs (P Ͻ 0.001). 41 In a case-control study comparing ACEI-associated (captopril and enalapril) cough in Hong Kong Chinese and Auckland Caucasians the incidence of cough in ACEI-users vs non-ACEI-users was 53% and 10% for Chinese and 18% and 5% for Caucasians (P Ͻ 0.001). 41 In a lisinopril study the incidence of cough following drug rechallenge was 31%, 43 and in a benazepril study 21% withdrew because of cough. 45 In contrast, in a study of 79 hypertensive patients given fosinopril, the total reported inci- Extrapolated from plasma concentration/activity plot. 31 dence of cough was 29%, 47 and none were withdrawn for cough. This appears to be a lower incidence of cough in Chinese than found with the other ACEIs cited above. In two separate studies (not among Chinese), which involved 24 patients each, patients with ACEI-induced cough were switched from another ACEI to fosinopril. In both studies there was a significant reduction in cough occurrence, frequency and severity (P Ͻ 0.001 48 and P р 0.0002 49 ) for each of the measurements. Cough with captopril has been related to higher doses and renal impairment leading to accumulation 50, 51 which could be lessened with fosinopril because of dual (renal/hepatic) excretory pathways. 49 Perhaps these observations explain the differences noted above.
Discussion
Based on these data, and with the exception of some pharmacokinetic measurements in the selected ACEIs which have been studied, there appears to be few differences among the pharmacokinetics of ACEIs between Chinese and Caucasians.
Only single-dose pharmacokinetic studies in normal volunteers were carried out with cilazapril and perindopril. With perindopril, and to a lesser extent cilazapril, there was a relatively short duration of effective ACE inhibition (Ͻ80% after 12 h) and for perindopril more rapid absorption and a higher concentration-time curve for Chinese than for Caucasians. These kinetics were also associated with a relatively poor blood pressure lowering effect. For cilazapril, plasma clearance was higher among Chinese. It is possible that these conclusions would have been different had steady-state pharmacokinetic data been available. Fosinopril pharmacokinetics are similar in normal Chinese and Caucasian
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In Chinese with CHF or other conditions in which the elimination pathway may be affected, there is data only for fosinopril, the only ACEI with a dual (hepatic and renal) elimination mode. In this case, there appeared to be no hazard induced by the heart failure condition and no significant differences among normal, hypertensive or heart failure patients, whether Chinese or Caucasian, in pharmacokinetics or pharmacodynamics, following single doses or at steady state.
In normal or hypertensive subjects ACEIs generally showed good blood pressure lowering efficacy in Chinese with the exception of perindopril and cilazapril (single dose studies in normotensives) where there appeared to be comparatively less blood pressure lowering (cilazapril) compared to Caucasians or a relatively short-term effect for either group (perindopril). The blood pressure lowering efficacy in Chinese of benazepril, enalapril, fosinopril and spirapril was adequately demonstrated in these studies.
Chinese experience more cough from ACEIs (captopril and enalapril) than Caucasians. Why this may be so remains to be explained. Data suggest that fosinopril may not induce cough in as many subjects as other ACEIs, 49, 52 and this seems to be true of Chinese as well. 47 The mechanism underlying this effect and the actual significance of it also await further investigation.
It appears, then, that ethnic differences between Chinese and Caucasians with respect to ACE and AGT gene polymorphism, which might be expected to differentially affect the action of ACEIs in these two ethnic groups, do not, in fact, have such an effect. There are data which may explain this paradox. Gene titration studies in mice using both the angiotensinogen (AGT) and ACE genes have shown that variations of angiotensin II (Ang II) levels are linked to changes in blood pressure, while variations in ACE levels, which may be considerable, are not associated with such changes. 53 As ACE levels decrease, the level of Ang I increases and with it the rate of its conversion to Ang II, thus maintaining Ang II levels. Why, then, does ACE inhibition lower Ang II levels? Because once ACE inhibition at the level of 80-90% occurs, the compensatory increase in Ang I levels approaches a plateau, at which point Ang II levels may then be significantly reduced. 53 This seems to set the clinically significant level of ACE inhibition at 80+%, a percent that correlates with clinical efficacy.
In conclusion, among the three ACEIs in which there are pharmacokinetic and pharmacodynamic data, fosinopril has no significant differences between Chinese and Caucasians and has a long duration of ACE inhibition. Cilazapril and perindopril show some minor differences in pharmacokinetics between Chinese and Caucasians and a somewhat lesser duration of ACE inhibition which may or may not be related to these ethnic differences. There appears to be evidence of the blood pressure lowering efficacy of a number of these ACEIs in Chinese, and there are pharmacokinetic data to support the use of fosinopril in congestive heart failure where elimination pathways may be impaired.
